What Has Been The Evolution of the Flow Cytometry In Oncology And Immunology Market in Recent Years?
The flow cytometry in oncology and immunology market has seen considerable growth due to a variety of factors.
•The oncology and immunology sector of the flow cytometry market has been expanding swiftly in the past few years. It has been forecasted to rise from $2.11 billion in 2024 to $2.33 billion in 2025, with a compound annual growth rate (CAGR) of 10.4%.
Factors contributing to this surge during the historic period include progress in cancer research, growth of research in immunology, advancements in diagnostic applications, an upswing in autoimmune diseases, along with development of drugs and clinical trials.
What Is the Forecasted Market Size and Growth Rate for The Flow Cytometry In Oncology And Immunology Market?
The flow cytometry in oncology and immunology market is expected to maintain its strong growth trajectory in upcoming years.
• The oncology and immunology sector of the flow cytometry market is projected to experience significant expansion in the upcoming years, with its worth anticipated to reach $3.46 billion in 2029, boasting a compound annual growth rate (CAGR) of 10.4%.
Various factors contribute to this predicted surge, including the merging with genomics and proteomics, increased interest in single-cell analysis, broadened use in the area of infectious diseases, rising cases of cancer, and the implementation of point-of-care flow cytometry. Noteworthy trends for the forecast period are immunophenotyping in relation to immunotherapy, the miniaturization of flow cytometry systems, multiparametric analysis, a shift towards spectral flow cytometry, as well as joint research initiatives.
What Factors Are Driving Growth In The Flow Cytometry In Oncology And Immunology Market?
The rise in cancer cases is anticipated to boost the advancement of flow cytometry within the field of oncology and immunology. Cancer, as a disease, encompasses a range of disorders marked by the unfettered development and dissemination of abnormal cells within the body. Flow cytometry is commonly employed in oncology and immunology for the examination of cancer and immune cells. For example, according to Macmillan Cancer Support, a healthcare charity based in the UK, there were 3 million cancer cases in 2020, a figure projected to increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Consequently, the rising prevalence of cancer is fueling the expansion of the flow cytometry market in the realms of oncology and immunology.
What Are The Main Segments Of The Global Flow Cytometry In Oncology And Immunology Market?
The flow cytometry in oncology and immunology market covered in this report is segmented –
1) By Type: Immunology, Oncology
2) By Technology: Cell-Based Flow Cytometry, Bead-Based Flow Cytometry
3) By Application: Translational Research, Clinical Research
4) By End User: Hospitals, Diagnostic Laboratories, Reference Laboratories, Pharmaceutical And Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, Other End Users
Subsegments:
1) By Immunology: Immune Cell Profiling, Cytokine Detection, T-Cell And B-Cell Analysis, Autoimmune Disease Testing
2) By Oncology: Cancer Cell Analysis, Tumor Microenvironment Studies, Minimal Residual Disease Detection, Biomarker Discovery And Validation
Pre-Book The Flow Cytometry In Oncology And Immunology Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Flow Cytometry In Oncology And Immunology Market?
The flow cytometry in oncology and immunology market is witnessing a growing trend of technological enhancements. To strengthen their market presence, eminent players in this sector are incorporating novel technologies into their operations. One notable development was in September 2022, when US-based medical technology company Becton Dickinson rolled out the BD Research Cloud for flow cytometry in oncology and immunology. This cloud-enabled software system is designed to streamline the flow cytometry process for research professionals working in diverse specialties, including immunology, virology, infectious diseases, and cancer surveillance. The goal is to facilitate more effective studies that yield faster insights. Becton Dickinson is using cutting-edge techniques like BD Horizon RealYellow and RealBlue Reagents in conjunction with the recently launched BD FACSDiscover S8 Cell Sorter equipped with BD CellView Image Technology. These tools aim to magnify the potential of flow cytometry, helping researchers to refine and progress their pioneering studies. Using industry-standard cloud architecture, the BD Research Cloud is particularly suited to BD equipment and reagents.
Who Are the Key Players in the Flow Cytometry In Oncology And Immunology Market?
Major companies operating in the flow cytometry in oncology and immunology market include:
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Merck KGaA
• Becton Dickinson and Company
• Laboratory Corporation of America Holdings
• Agilent Technologies Inc.
• Sartorius AG
• Beckman Coulter Inc.
• Bio-Rad Laboratories Inc.
• Sysmex Partec GmbH
• OPKO Health Inc.
• Miltenyi Biotec
• NeoGenomics Laboratories Inc.
• Luminex Corporation
• Q2 Solutions LLC
• DiaSorin S.p.A
• BioLegend Inc.
• Cytek Biosciences Inc.
• Cell Signaling Technology Inc.
• Standard BioTools Inc.
• Sony Biotechnology Inc.
• NanoCellect Biomedical Inc.
• Nexcelom Bioscience LLC
• CytoReason
What Is The Most Dominant Region In The Flow Cytometry In Oncology And Immunology Market?
North America was the largest region in the flow cytometry in oncology and immunology market in 2024. The regions covered in the flow cytometry in oncology and immunology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
